Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 26, 2011

Cepheid Eyes Two-Week Shipping for Xpert Flu Diagnostic in the U.S.

  • Cepheid expects to have its Xpert® Flu diagnostic available for shipping in two weeks, after receiving FDA clearance to market the product.The test, which runs on Cepheid's GeneXpert® System, detects and differentiates influenza A, influenza B, and the 2009 H1N1 influenza virus simultaneously in about one hour.

    "While molecular testing is widely recognized as the new gold standard for detection of influenza, it has generally been limited to highly complex laboratories,” Cepheid CEO John L. Bishop states. 'Xpert Flu empowers institutions with moderate complexity laboratories to have a molecular influenza test available to their physicians 24 hours a day."

    Xpert Flu requires less than two minutes hands-on time and uses a single-use cartridge design that enables on-demand STAT testing, according to Cepheid. It is also available as a CE mark in vitro diagnostic product.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »